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Abstract
Objective. A proportion of RA and SLE patients treated with standard doses of rituximab (RTX) display
inefficient B cell deletion and poor clinical responses that can be augmented by delivering higher doses,
indicating that standard-dose RTX is a sub-optimal therapy in these patients. This study aimed to inves-
tigate whether better responses could be achieved with mechanistically different anti-CD20 mAbs.
Methods. We compared RTX with obinutuzumab (OBZ), a new-generation, glycoengineered type II anti-
CD20 mAb, in a series of in vitro assays measuring B cell cytotoxicity in RA and SLE patient samples.
Results. We found that OBZ was at least 2-fold more efficient than RTX at inducing B-cell cytotoxicity in
in vitro whole blood assays. Dissecting this difference, we found that RTX elicited more potent comple-
ment-dependent cellular cytotoxicity than OBZ. In contrast, OBZ was more effective at evoking Fc gamma
receptor-mediated effector mechanisms, including activation of NK cells and neutrophils, probably due to
stronger interaction with Fc gamma receptors and the ability of OBZ to remain at the cell surface following
CD20 engagement, whereas RTX became internalized. OBZ was also more efficient at inducing direct cell
death. This was true for all CD19+ B cells as a whole and in naı¨ve (IgD+CD27) and switched (IgDCD27+)
memory B cells specifically, a higher frequency of which is associated with poor clinical response after
RTX.
Conclusion. Taken together, these data provide a mechanistic basis for resistance to rituximab-induced
B-cell depletion, and for considering obinutuzumab as an alternative B-cell depleting agent in RA and SLE.
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Rheumatology key messages
. Obinutuzumab induces superior B cell cytotoxicity to rituximab in RA and SLE patient samples.
. B cells from RA and SLE patients internalize rituximab more rapidly than obinutuzumab.
. Obinutuzumab is superior to rituximab at evoking Fc gamma receptor-dependent and -independent effector
mechanisms in RA and SLE.
Introduction
Incomplete B cell depletion following treatment with the
anti-CD20 mAb rituximab (RTX) is associated with poor
clinical response in both RA [1] and SLE [2], whereas
enhanced B cell depletion achieved using additional
doses of RTX in RA [3] and prolonged duration of deple-
tion are associated with a better clinical response in SLE
[4]. Therefore, these data indicate that achieving com-
plete, durable B cell depletion will improve clinical re-
sponse in both RA and SLE.
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B cell subpopulations may be defined as naı¨ve
(IgD+CD27), unswitched memory cells (IgD+CD27+),
switched memory cells (IgDCD27+) and double negative
(DN) cells (IgDCD27). Poor clinical response to RTX in
both RA and SLE is associated with a higher number and/
or frequency of CD27+ memory cells [1, 2, 5] and also with
DN B cells in RA [5], suggesting that resistance to deple-
tion of different B cell subpopulations is clinically relevant
[6]. Further, a greater frequency of IgDCD27+ switched
memory cells and DN cells, but not IgD+CD27 naı¨ve or
IgD+CD27+ unswitched memory cells, was detectable in
peripheral blood of patients 4 weeks after a single low
dose of RTX (500 mg), prior to organ transplantation. In
contrast, B cell composition in lymph nodes and spleen
[7] revealed the presence of IgD+CD27 naı¨ve and
IgD+CD27+ unswitched memory cells [8, 9], despite op-
sonization with RTX [8, 9], which suggests that in lymph
nodes depletion by RTX was compromised. Collectively,
these findings suggest that RTX depletes naı¨ve cells and
IgD+CD27+ unswitched memory cells more efficiently than
IgDCD27+ switched memory cells and DN cells, particu-
larly in lymphoid tissues [10].
Anti-CD20 mAbs evoke distinct cytotoxic mechanisms:
complement-dependent cellular cytotoxicity (CDC), Fc
gamma receptor (FcgR)-mediated depletion through cel-
lular effectors including antibody-dependent cellular cyto-
toxicity (ADCC) and antibody-dependent cellular
phagocytosis, and direct cell death (DCD). Good clinical
response to rituximab in both RA [11] and SLE [12] is
associated with the higher affinity 158 V polymorphism
in CD16a (FcgRIIIa) suggesting that FcgR-mediated mech-
anisms are important for B cell depletion. Moreover, SLE-
associated defects in complement [13], NK cells [14, 15]
and neutrophils [16] and acquired defects in phagocytosis
[1618] may impact the efficiency of anti-CD20 mAbs [19].
Anti-CD20 mAbs can be categorized as types I and II.
Type I anti-CD20 mAbs, such as RTX, redistribute CD20
into lipid rafts, a property that facilitates clustering and
complement activation, but also mAb internalization,
which is partly driven by cis-mediated engagement of
FcgRIIb [20, 21], reducing surface accessible mAb for en-
gagement with FcgR on effector cells [22] such as NK
cells, neutrophils and macrophages [23]. Type II mAbs
such as obinutuzumab (OBZ, GA101) do not undergo ef-
ficient redistribution, clustering or internalization.
Accordingly, in follicular and mantle cell lymphoma high
target cell expression of FcgRIIb was shown to be asso-
ciated with poor clinical response to RTX [20, 24].
Other type I mAbs, ofatumumab and ocrelizumab, have
been used in clinical trial settings in RA and/or SLE, re-
spectively [25, 26]. To date, no type II mAb has been used
in these diseases. However, OBZ has been used in
chronic lymphocytic leukaemia and shown to be more ef-
fective than RTX [27]. OBZ has also been glycoengineered
with an afucosylated Fc facilitating enhanced affinity for
CD16a [28], which is the basis of its superior potency in
NK-mediated ADCC [29] and antibody-dependent cellular
phagocytosis [30]. Therefore, data on the pre-clinical ac-
tivity of RTX and OBZ in RA and SLE would be of clear
clinical importance to understanding whether OBZ may at
least partly overcome autoimmune disease-related resist-
ance mechanisms.
Our previous work showed that internalization of RTX
compromised its ability to delete B cells in vitro and that
glycosylated OBZ was superior to RTX in whole blood B
cell depletion assays in both RA and SLE [31]. Here, we
compared the ability of RTX and OBZ to evoke different
effector mechanisms and delete target B cells from pa-
tients with RA and SLE. We show that OBZ is at least
2-fold more efficient than RTX at inducing cytotoxicity of
these B cells, that it internalizes less rapidly than RTX from
the autoimmune B cells, and that it is less efficient than
RTX at recruiting complement, but significantly more
potent at evoking FcgR-mediated activation of NK cells
and neutrophils as well as FcgR-independent direct cell
death. We also show that IgDCD27+ switched memory
cells and DN cells express significantly lower levels of
CD20 than IgD+CD27+ unswitched memory cells, poten-
tially contributing to their apparent resistance to RTX-
induced depletion.
Methods
All participants of this study provided consent according
to the Declaration of Helsinki and this study was approved
by the National Research Ethics Service committee,
London-Bentham. All patients with RA satisfied the
ACR/EULAR classification criteria [32] and all patients
with SLE met the ACR classification criteria [33]. The pa-
tient demographics are shown in the supplementary
Tables S1 and S2, available at Rheumatology Online.
Antibodies and reagents
Anti-CD20 mAbs used in the studies include RTX, OBZ
and non-glycoengineered, wild-type glycosylated OBZ
(OBZGly) and in some experiments OBZ with a mutated
Fc portion (P329G LALA) that does not engage any Fc-
mediated effector functions [34] (OBZ-PG LALA). Roche
Innovation Center Zu¨rich, Switzerland generated all anti-
CD20 mAbs except RTX, which was a kind gift from the
pharmacy of University College Hospital, UK, and AT10
(FcgRII antagonist) [35] was produced in-house.
Flow cytometry and B cell isolation
Fluorochrome-conjugated mAbs anti-CD3 (phycoerythrin
(PE)-Cy7), anti-CD15 (FITC): anti-CD16 (allophycoyanin),
anti-CD19 (Alexa Fluor 700), anti-CD45 (PE), anti-CD56
(PE), anti-CD107a (Brilliant Violet 421), anti-CD11b (PE)
and anti-CD62L (allophycoyanin), and propidium iodide
(PI) and annexin V (Av) (FITC) were obtained from BD
Biosciences (Oxford, UK) and Biolegend, London, UK. In
addition to forward- and side-scatter characteristics, we
identified B cells as CD19+, T cells as CD3+, NK cells as
CD356+ and neutrophils as CD15+ by flow cytometry
using a Becton Dickinson LSR Fortessa cell analyzer.
Peripheral blood mononuclear cells were separated from
whole blood by Ficoll-Hypaque density gradient and B
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cells were isolated using EasySep Human B Cell
Enrichment Kit (Stemcell Technologies, Cambridge, UK).
Whole blood B cell depletion assays
Briefly, 300ml of freshly drawn whole blood anti-coagu-
lated with heparin was incubated with or without mAbs
at 1 mg/ml for 24 h at 37 C and 5% CO2 before analysing
with a flow cytometer, as described previously [31]. The
percentage B cell depletion was calculated from the pro-
portion of B cells to T cells remaining after treatment and
defined as the cytotoxicity index (CTI) as described pre-
viously [28, 31].
Surface fluorescence-quenching assays
Surface fluorescence-quenching assays were performed
as described previously [23, 31] to assess internalization
of mAbs by B cells. Isolated B cells were incubated for 6 h
with Alexa-488 conjugated mAbs at a concentration of
5mg/ml before analysing by flow cytometry.
CDC cytotoxicity assays
CDC assays were performed as previously described [36].
Isolated B cells were incubated with mAbs at a concen-
tration of 10 mg/ml for 30 min at 37 C and 5% CO2 stained
with anti-CD19, Av and PI and the frequency of
CD19+Av+PI+ cells assessed by flow cytometry. We
used freshly collected normal healthy human serum as a
source of complement and part of the serum was heat
inactivated at 56 C for 30 min to produce heat inactivated
serum (HIS). The ability of mAbs to induce CDC was as-
sessed by the relative frequency of CD19+Av+PI+ cells in
samples incubated either with normal healthy serum or
with HIS.
Direct cell death
Isolated B cells were incubated in RPMI supplemented
with 10% heat inactivated fetal calf serum with or without
mAbs at a concentration of 10 mg/ml for 6 h at 37 C and
5% CO2 and stained and analysed as for CDC. The fre-
quency of CD19+Av+ cells in samples incubated with
mAbs compared with samples incubated without mAbs
represented the ability of mAbs to induce DCD.
NK cell degranulation assays
NK cell degranulation was assessed using samples from
the whole blood B cell depletion assay by measuring the
expression of CD107a or lysosome associated membrane
protein 1, which is up-regulated upon activation of NK
cells and correlates with NK cell mediated ADCC
[37, 38]. The extent of CD16a loss was also used as an
indirect measure of NK cell activation [39, 40].
Neutrophil activation assays
We assessed neutrophil activation in the whole blood
assay by measuring increases in the mean fluorescent
intensity (MFI) of CD11b or decreases in MFI of CD62L
on CD15+ neutrophils by flow cytometry [41, 42] in sam-
ples incubated with mAbs compared with samples incu-
bated without mAbs.
Statistical analysis
Data were analysed using Prism version 5.0 (GraphPad
Software, La Jolla, CA, USA). The MannWhitney test or
Wilcoxon’s matched-pairs signed rank test was used to
compare groups as appropriate. Spearman’s correlation
coefficient was used to analyse for correlation.
Results
Type II mAbs are more efficient than type I at indu-
cing B cell cytotoxicity
To assess the effect of types I and II mAbs on B cell cyto-
toxicity in RA and SLE samples, whole blood B cell de-
pletion assays were performed as described previously
[31] (supplementary Fig. S1, available at Rheumatology
Online). OBZ was >2-fold more efficient than RTX at
deleting B cells from patients with RA (n = 31) and SLE
(n = 34) and both non-glycomodified OBZGly and OBZ
were more efficient than RTX, in all samples tested
(Fig. 1A and supplementary Table S3, available at
Rheumatology Online). In both RA and SLE, the median
CTI of OBZ was significantly greater than the CTI of
OBZGly and RTX. The CTI of OBZGly was significantly
higher than the CTI of RTX in both RA and SLE. In RA,
the median (interquartile range) CTI of RTX, OBZGly and
OBZ was 29 (1350), 60 (4770) and 67 (6077), respect-
ively, and in SLE was 19 (1139), 40 (3153) and 59
(5270), respectively. Both type II anti-CD20 mAbs,
OBZGly and OBZ, demonstrated superior efficiency of B
cell cytotoxicity to the type I anti-CD20 mAb, RTX, in all
individual samples from patients with RA and SLE (data
not shown).
There were no significant correlations between CTI of
RTX or CTI of OBZ and patient’s age, serum complement
and/or IgA levels in samples from patients with SLE (data
not shown).
Thus, in both RA and SLE, there was a hierarchy of
mAb-induced B cell depletion: RTX<OBZGly<OBZ.
The superior efficiency of OBZGly (having a non-glycomo-
dified Fc similar to RTX) suggests that its type II nature
accounts for the difference between the two types of
mAbs in the efficiency of B cell depletion in the whole
blood assay, whereas the increased efficiency of OBZ
compared with OBZGly is attributable to afucosylation of
the Fc portion.
B-cells internalize RTX more rapidly than OBZ
RTX was internalized more extensively than OBZ after 6 h
of incubation with a median (range) percentage of surface
accessible RTX vs OBZ of 55 (5157) vs 83 (8184), re-
spectively, in RA (n = 5) and 60 (4977) vs 76 (7080), re-
spectively, in SLE (n = 8) (Fig. 1B). Internalization of RTX
and, to a smaller extent, OBZ, was partially inhibited in the
presence of the FcgRII-blocking mAb AT10 (Fig. 1B), simi-
lar to our previous observations using a non-glycomodi-
fied type II antibody variant [31].
www.rheumatology.oxfordjournals.org 1229
OBZ induces superior B-cell cytotoxicity
RTX is more efficient than OBZ at inducing
CDC cytotoxicity
The frequency of lysed B cells (CD19+Av+PI+) was signifi-
cantly greater in samples incubated with RTX in the pres-
ence of normal healthy serum compared with HIS
(supplementary Fig. S2, available at Rheumatology
Online) with a median (range) difference of 10.9%
(8.121%) whereas the difference for OBZ was 4.8%
(0.96.5%) (Fig. 1C). The mean (S.D.) fold increase in
lysed cells in samples incubated with normal healthy
serum vs HIS was 1.9 (0.5) and 1.2 (0.2) for RTX and
OBZ, respectively (Fig. 1D). Thus, RTX was superior to
OBZ at evoking CDC.
OBZ is more efficient than RTX at activating NK cells
The ability of the mAbs to induce NK cell activation in the
whole blood B cell depletion assay, shown in Fig. 2,
allowed assessment of NK cell degranulation (CD107a in-
crease) relative to expression of CD16a. The highest pro-
portion of CD107a+ NK (CD3CD56+) cells was seen in
the CD56+CD16 fraction (Fig. 2) suggesting that
degranulating NK cells had down-regulated CD16, as pre-
viously reported [39].
In equivalent assays comparing RTX and OBZ, after
24 h of incubation in the absence of mAbs, there was no
significant difference in the frequency of NK cells,
CD107a+ NK cells, CD16+ NK cells or B cells between
patients with RA (n = 18) and SLE (n = 23) (Fig. 3A).
However, in both RA and SLE, the median (range) fre-
quency of CD3CD56+CD107a+ activated NK cells was
significantly higher in samples incubated with OBZ com-
pared with RTX, 5.1% (1.922%) vs 2.8% (0.314%) and
5.5% (0.612%) vs 4.3% (1.28.9%), respectively, and the
median (range) frequency of CD16+ NK cells was signifi-
cantly lower, 69% (3694%) vs 89% (8397%) and 66%
(4291%) vs 84% (6195%), respectively (Fig. 3B). Also,
there was a significantly higher fold-increase in the fre-
quency of CD3CD56+CD107a+ NK cells in samples incu-
bated with OBZ compared with RTX in SLE (Fig. 3B).
NK cell activation, as assessed by either gain of
CD107a or loss of CD16, or the fold increase in the fre-
quency of CD3CD56+CD107a+ NK cells was greater in
RA compared with SLE (Fig. 3B). NK cell activation, as
FIG. 1 Whole blood B cell depletion, internalization and CDC elicited by anti-CD20 mAbs in RA and SLE patient samples
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(A) Whole blood B-cell depletion in samples from patients with RA (n = 31) and SLE (n = 34). The horizontal line in the box
represents the median, the box represents the interquartile range and the whiskers represent the range. (B) Surface
fluorescence-quenching assay in RA (n = 5) and SLE (n = 8) samples with or without prior incubation with anti-FcgRII
blocking mAb, AT10. (C) The frequency of lysed CD19+Av+PI+ B cells in SLE (n = 9) samples. (D) The fold increase
in samples incubated with normal healthy serum (NHS) vs heat inactivated serum (HIS). *P < 0.05; **P < 0.005;
***P < 0.0001; and NS, not significant. OBZGly, obinutuzumab with glycosylated Fc; OBZ, obinutuzumab.
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assessed by the frequency of CD3CD56+CD107a+ NK
cells, by RTX and OBZ correlated significantly with that
in samples incubated without mAbs, with r2 = 0.89,
P< 0.05 and r2 = 0.78, P< 0.05, respectively, in RA
(Fig. 3C) and r2 = 0.52, P< 0.05 and r2 = 0.36, P< 0.05,
respectively, in SLE (Fig. 3D). However, correlations were
stronger in RA compared with SLE.
We next investigated the effect of Fc engineering on
activation of NK cells using OBZGly and OBZ-PG LALA,
which completely lacks FcgR engagement [43]. OBZ was
more efficient than OBZGly and RTX in depleting B cells in
the whole blood assay in both RA (n = 18) and SLE (n = 23)
(Fig. 4A) with an increasing hierarchy in the frequency of,
and fold-increase in, CD3CD56+CD107a+ NK cells as
follows: no mAbs = OBZ-PG LALA>RTX>OBZGly>OBZ
(Fig. 4BD). The frequency of CD3CD56+CD16+ NK cells
was significantly lower in samples incubated with OBZ
compared with other samples (Fig. 4D). The frequency
of CD3CD56+CD16+ NK cells was also lower in samples
incubated with OBZGly compared with RTX in RA, but not
SLE (Fig. 4D).
Thus, the ability of mAbs to up-regulate the expression
of CD107a on CD3CD56+ NK cells was greater in RA
compared with SLE, such that the mean fold difference
in samples incubated with RTX, OBZ-PG LALA, OBZGly
and OBZ compared with samples incubated without
mAbs was 1.2, 1.5, 1.9 and 3.1, respectively, in RA and
1.5, 0.8, 1.4 and 1.8, respectively, in SLE (Fig. 4C).
OBZ is more efficient than RTX at
activating neutrophils
Neutrophils have been proposed as mAb effector cells
[41]. We assessed the ability of mAbs to induce neutrophil
activation by measuring the expression of CD11b and
CD62L, as described previously [42] and shown in sup-
plementary Fig. S3, available at Rheumatology Online.
CD11b forms part of the b-integrin (Mac-1) complex and
genetic variants of this complex have been associated
with lupus-related phagocytic defects [44]. Upon neutro-
phil activation the surface expression of CD11b is
up-regulated whereas the expression of the adhesion
molecule CD62L is down-regulated [41, 42]. The MFI of
CD11b in samples incubated with mAbs was significantly
higher in both RA (n = 10) and SLE (n = 22) (Fig. 5A) com-
pared with samples incubated without mAbs. In both RA
and SLE, we noted significant correlations between the
MFI of CD11b in samples incubated without mAbs and
that in samples incubated with RTX (r2 = 0.81, 0.82, re-
spectively) whereas significant correlation for OBZ was
noted in SLE (r2 = 0.81), but not RA (Fig. 5B). We noted
a hierarchy in the ability of mAbs to up-regulate CD11b
such that the MFI of CD11b was lower in samples incu-
bated with RTX<OBZGly<OBZ, as in the case of NK cell
activation. The MFI of CD62L was also greater in samples
incubated with RTX>OBZGly>OBZ (Fig. 5C). In both RA
and SLE, we noted significant correlations between the
MFI of CD62L in samples incubated without mAbs and
FIG. 2 NK cell degranulation assay: relationship between NK cell expression of CD107a and CD16
Flow cytometry-gating strategy to assess NK cell degranulation. Whole blood samples were incubated with or without
mAbs for 24 h before analysing by flow cytometry. NK cells were identified based on forward- and side-scatter char-
acteristics and CD56+CD3. The frequency of CD3CD56+CD107a+ cells represented activated/degranulated NK cells.
The relative frequency of activated CD107a+ NK cells based on CD16 expression in three subpopulations of CD3CD56+
NK cells was identified based on the relative expression of CD16 (boxed as A, B and C above). FSC: forward-scatter;
SSC: side-scatter.
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that in samples incubated with RTX (r2 = 0.93, 0.91, re-
spectively) and OBZ (r2 = 0.64, 0.71, respectively)
(Fig. 5D). Thus, the hierarchy of mAbs in their ability to
activate neutrophils was OBZ>OBZGly>RTX. Thus,
these data indicated that type II mAbs are superior to
RTX in activating neutrophils in the whole blood assay in
both RA and SLE samples. OBZ-PG LALA did not elicit
significant changes for either marker in both RA (n = 7) and
SLE (n = 12) compared with samples incubated without
mAbs.
OBZ is more efficient than RTX at inducing direct
cell death
We assessed DCD, using the Av assay as shown in sup-
plementary Fig. S4, available at Rheumatology Online. The
ability of OBZ to induce DCD was greater than that of RTX
for both CD19+ cells as a whole and the B cell sub-
populations IgD+CD27 naı¨ve cells and IgDCD27+
switched memory cells (Fig. 6A; RA, n = 5 and SLE, n = 4).
The proportion of Av+ cells was highest for DN cells >
IgD+CD27+ unswitched memory cells > IgDCD27+
switched memory cells > IgD+CD27 naı¨ve cells.
Nonetheless, OBZ was superior to RTX at inducing DCD.
Sensitivity of B cell subpopulations to deletion/DCD:
relationship with expression of CD20, FcgRIIb
and internalization
B cell subpopulations displayed varying ability to internal-
ize mAbs such that IgDCD27+ switched memory cells
internalized mAbs less than other B cell subpopulations;
and IgD+CD27+ unswitched memory cells internalized
mAbs to a greater extent than other B cell subpopulations
(Fig. 6C). Antagonizing the effects of FcgRIIb with AT10
significantly reduced internalization in both cases. When
compared with naı¨ve and IgDCD27+ switched memory
cells, IgD+CD27+ unswitched memory cells had signifi-
cantly greater expression of CD20 (Fig. 6B) and FcgRIIb
(Fig. 6D) and displayed significantly greater ability to in-
ternalize mAbs, whereas naı¨ve and IgDCD27+ switched
memory cells had significantly lower expression of CD20
and FcgRIIb and displayed significantly lower levels of in-
ternalization. DN cells had variable levels of expression of
CD20 and FcgRIIb, but internalized RTX to a significantly
greater extent than IgDCD27+ switched memory cells.
B cells from both RA and SLE samples consistently dis-
played low levels of OBZ internalization. Thus, there was
no clear relationship between the susceptibility of B cell
FIG. 3 Obinutuzumab is more efficient than rituximab at activating NK cells in RA and SLE patient samples
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the frequency of CD3CD56+ NK cells, CD3CD56+CD107a+ NK cells, CD3CD56CD16+ NK cells as a percentage of
total NK cells and CD19+ cells after incubation in the absence (A) or presence (B) of RTX and OBZ and their relationship in
RA (C) and SLE (D). Horizontal lines represent the median. *P < 0.05; **P < 0.005; ***P < 0.0001; ns: not significant; r2:
Spearman’s correlation coefficient. NT: not treated; OBZGly: obinutuzumab with glycosylated Fc; OBZ: obinutuzumab.
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subpopulations to mAb-induced DCD and the ability to
internalize mAbs or to express CD20 or FcgRIIb.
Discussion
Our data show that OBZ, a type II anti-CD20 mAb with a
glycomodified Fc, demonstrated at least 2-fold greater
potency at deleting B cells from whole blood samples
from patients with RA and SLE compared with RTX. This
increased activity of OBZ was effected predominantly
through FcgR-mediated effector mechanisms and DCD.
In contrast, RTX recruited complement more efficiently
for CDC, but was rapidly internalized and significantly
less efficient at evoking ADCC and DCD. Our subsequent
analysis revealed that the expression of the CD20 target
molecule was less on IgDCD27+ switched memory and
DN cells, perhaps accounting for their relative resistance
to removal by RTX.
Target B cells can be deleted with anti-CD20 mAb
through multiple mechanisms, with type I mAb engaging
complement more effectively than type II mAb. Our
findings of superior efficiency of OBZ over RTX at inducing
B cell death, despite its inferior ability to recruit
complement, are consistent with previous data derived
from in vitro studies on malignant B cells and/or cell
lines [22, 28, 45, 46]. The superior efficiency of OBZ in
the whole blood assay was noted in all individual samples.
Complement defects are characteristic of certain autoim-
mune conditions, such as SLE [13], where, we speculate,
OBZ may provide a mechanistic advantage over RTX.
The superior efficiency of OBZ in the whole blood assay
despite inferior ability to evoke CDC suggests that the
predominant mode of action of OBZ is through FcgR-
mediated effector mechanisms and/or DCD. While there
was no difference between patients with RA and SLE in
the frequency of activated NK cells that lacked CD16 ex-
pression and/or expressed CD107a, NK cells from pa-
tients with both RA and SLE responded less well to
stimulation with RTX compared with OBZ. We found that
activation of NK cells by anti-CD20 mAbs is also asso-
ciated with down-regulation of CD16 revealing remarkable
differences in activation of NK-cell subpopulations based
on the relative expression of CD16 and up-regulation of
the degranulation marker, CD107a. Whereas RTX was
less efficient at activating NK cells in both RA and SLE,
OBZ induced a greater fold-increase in activating NK cells
FIG. 4 Obinutuzumab induces superior NK cell-mediated cellular cytotoxicity to rituximab in RA and SLE patient samples
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in samples from patients with RA compared with SLE,
suggesting SLE-associated NK cell defects may also con-
tribute to poor depletion with RTX [14, 15, 47].
The relative inefficiency of RTX at evoking ADCC in vitro
may, at least partly, be due to internalization of mAbs
leading to reduced engagement with FcgR-bearing ef-
fector cells, as shown previously [22, 36]. Afucosylation
of Fc increases the affinity of IgG1 mAbs for CD16a with
little effect on complement binding [48], which may ex-
plain the superior efficiency of OBZ at activating NK
cells in the whole blood assay even in the presence of
complement [49]. Therefore, the superior efficiency of
OBZ at activating NK cells may be attributable to a greater
surface accessibility owing to its type II nature and a
greater affinity for CD16 conferred by afucosylation of Fc.
Our findings of superior neutrophil activation by OBZ
compared with RTX in RA and SLE samples are consistent
with studies in malignant B cells [41]. Polymorphisms of
CD16b may at least partially account for the variability in
mAb-induced activation, most notable for RTX whereas
afucosylation may have reduced this variability, as
described previously [41]. A number of polymorphisms
of CD11b associated with SLE may have contributed to
the variability between patients in neutrophil activation
[44], but regardless, glycoengineered OBZ was more effi-
cient than wild type OBZ and RTX at inducing neutrophil
activation.
Following RTX treatment, a small number of IgDCD27+
switched memory cells and DN cells are detectable in the
peripheral blood of patients with RA and SLE [5, 6, 50]
suggesting relative resistance to depletion by RTX, per-
haps due to lower levels of CD20 on IgDCD27+ switched
memory cells and DN cells compared with IgD+CD27+
unswitched memory cells. Surface expression of IgD
and the activation state of B cells may also influence in-
ternalization of mAbs, compromising their cytotoxicity
[31]. Regardless, OBZ induced greater DCD in vitro in
CD19+ cells and IgDCD27+ switched memory cells
FIG. 5 Obinutuzumab is more efficient than rituximab at activating neutrophils in RA and SLE patient samples
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from patients with RA and SLE, compared with RTX.
These findings are similar to that in malignant B cells [28].
The main limitations of this study are that all experi-
ments were performed in vitro. Therefore, these results
showing superior efficiency of OBZ to RTX may not trans-
late into more efficient B cell depletion in vivo and/or in
different tissues such as the lymph node, kidney and joint.
Further, concomitant therapies may influence the pharma-
cokinetics of OBZ and have an impact on its overall effi-
ciency to deplete B cells in patients with RA and SLE.
Disease- and host-associated immune deficiencies may
contribute to incomplete depletion with RTX in some pa-
tients with RA and SLE leading to worse clinical re-
sponses. Phase II clinical studies are on-going to
evaluate the efficacy of OBZ in patients with lupus neph-
ritis (NCT02550652) and hypersensitized patients
with end-stage renal disease awaiting transplantation
(NCT02586051). Our results showing superior efficiency
of OBZ over RTX, noted in the whole blood assay,
are likely due to FcgR-mediated effector mechanisms
and DCD.
This study provides compelling mechanistic reasons for
expecting better outcomes with OBZ as an alternative B
cell depleting agent for patients with RA, and SLE in
particular.
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